ESR1 and breast carcinoma: Because of the heightened interest in breast cancer, particularly the estrogen receptor-positive subtype, a number of investigations have been carried out to understand the basis of tamoxifen resistance and a number of genes, factors and signaling pathways are now believed to contribute to resistance to tamoxifen4–8.